Satavaptan
Jump to navigation
Jump to search
Template:Short description Template:Short description <templatestyles src="Infobox drug/styles.css"/> Script error: No such module "Infobox".Script error: No such module "TemplatePar".Template:Infobox drug/maintenance categories
Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin V2 receptor antagonist[1] which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites.[2] Development was discontinued in 2009.[3]
References
<templatestyles src="Reflist/styles.css" />
Script error: No such module "Check for unknown parameters".